Cryoport vs Maravai LifeSciences
CYRX and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYRX and MRVI compare
Maravai LifeSciences is the larger company, worth 1.9 times as much as Cryoport ($2.0B against $1.0B).
Cryoport grew revenue faster over the last twelve months (11.8% versus 10.7% for Maravai LifeSciences).
Cryoport keeps more of each dollar of sales as profit, with a net margin of −21.5% compared with −30.8% at Maravai LifeSciences.
Cryoport scores higher on the StockData Score (10 against 8 for Maravai LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYRX | MRVI |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $2.0B |
| Share price | $19.89 | $7.54 |
| Change, 1 year | 125% | 132% |
| Change, 5 years | −72.5% | −79.9% |
| Beta (5Y) | 1.92 | 1.01 |
| Employees | 738 | 435 |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.2× (better) | 9.2× |
| P/B | 2.1× (better) | 10.0× |
| FCF yield | −1.9% | −0.68% (better) |
| Fair value | $15.89 | $2.60 |
| Margin of safety | −25.2% (better) | −190% |
| Growth | ||
| Revenue growth (TTM) | 11.8% (better) | 10.7% |
| Revenue growth, 5Y average | 17.5% (better) | −8.1% |
| Net income growth (TTM) | −158% | – |
| EPS growth (TTM) | −178% | – |
| Profitability | ||
| Gross margin | 46.9% (better) | 39.1% |
| Operating margin | −20.0% (better) | −45.4% |
| Net margin | −21.5% (better) | −30.8% |
| FCF margin | −9.8% | −6.2% (better) |
| Return on equity | −8.3% (better) | −29.8% |
| Return on invested capital | −32.9% | −27.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.75 |
| Interest coverage | −18.3× | −4.6× (better) |
| Current ratio | 2.04 | 4.66 (better) |
| Altman Z-score | 1.38 | 4.54 (better) |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 93.9% | 55.5% |
| Held by insiders | 3.6% | 3.6% |
| Insider net buying, 12 months | −$6.3M | $115K (better) |
| Short interest, % of float | 7.1% | 5.6% |
Go deeper
- CYRX stock overview
- CYRX income statement
- CYRX valuation and score
- MRVI stock overview
- MRVI income statement
- MRVI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.